Regulatory Pathways & Compliance Solutions

Supporting Universities, Drug Manufacturers, and Startups in Bringing Innovations to Market

Bridging Innovation and Regulatory Success

Navigating regulatory pathways can be one of the most challenging and time-consuming aspects of drug development.

Whether you're a university research team, an emerging biotech startup, or an established pharmaceutical manufacturer, ensuring regulatory compliance while accelerating drug development is critical to success.

Who We Support

Universities & Research Institutions

Translating academic discoveries into real-world therapies.

Navigating the transition from preclinical research to IND submissions.

Ensuring compliance with FDA, EMA, and global regulatory standards.

Drug Manufacturers

Streamlining GMP compliance for pharmaceutical production.

Developing scalable regulatory strategies for clinical trials and beyond.

Implementing quality control systems to meet evolving standards.

Startups & Emerging Biotechs

Identifying the right regulatory pathway (IND, NDA, BLA, 510(k), etc.)

Reducing time-to-market with efficient submission strategies.

Building regulatory roadmaps that align with funding and commercialization goals.

How Parimer Helps

Regulatory Strategy & Compliance Support

Comprehensive guidance on FDA, EMA, and global requirements
Assistance with preclinical and clinical trial applications
Risk assessment & regulatory gap analysis

Manufacturing & GMP Readiness

Facility compliance audits & documentation
GMP training & implementation strategies
Vendor qualification & supply chain compliance

Submission & Approval Acceleration

Preparing IND, NDA, BLA, and 510(k) filings
Regulatory writing & dossier compilation
FDA meeting preparation & response strategies

Let’s Build Your Regulatory Success Story

Regulatory hurdles shouldn’t hold back innovation. Whether you’re developing new therapeutics, working on a university research project, or bringing a novel drug to market, Parimer is your trusted partner for navigating the complexities of compliance.